XE991

• Description :

  XE 991, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Potassium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/xe991.html

• Purity :

  99.69

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1C2=C(C=CC=C2)C(CC3=CC=NC=C3)(CC4=CC=NC=C4)C5=CC=CC=C15

• Molecular Formula :

  C26H20N2O

• Molecular Weight :

  376.45

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Wang HS, et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998 Dec 4;282 (5395) :1890-3.|[2]Zaczek R, et al. Two new potent neurotransmitter release enhancers, 10,10-bis (4-pyridinylmethyl) -9 (10H) -anthracenone and 10,10-bis (2-fluoro-4-pyridinylmethyl) -9 (10H) -anthracenone: comparison to linopirdine. J Pharmacol Exp Ther. 1998 May;285 (2) :724-30.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [122955-42-4]